Research ArticleArticle
Open Access
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations
Deepak R. Jadon, Nadia Corp, Danielle A. van der Windt, Laura C. Coates, Enrique R. Soriano, Arthur Kavanaugh, Tim Raine, Florian Rieder, Stefan Siebert, Michel Zummer, Sergio Schwartzman, James T. Rosenbaum, Brigitte Michelsen, Ramasharan Laxminarayan, Dongze Wu, Latika Gupta, Beverly Ng, Hannah Jethwa, Nick De Windt, Tania Gudu, Joseph Hutton, Denis O'Sullivan, Michele M. Luchetti, Matthew Stoll, Jasvinder A. Singh, Rosario Peluso, Judith Rademacher and M. Elaine Husni
The Journal of Rheumatology December 2022, jrheum.220317; DOI: https://doi.org/10.3899/jrheum.220317
Deepak R. Jadon
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Nadia Corp
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Danielle A. van der Windt
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Laura C. Coates
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Enrique R. Soriano
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Arthur Kavanaugh
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Tim Raine
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Florian Rieder
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Stefan Siebert
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Michel Zummer
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Sergio Schwartzman
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
James T. Rosenbaum
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Brigitte Michelsen
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Ramasharan Laxminarayan
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Dongze Wu
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Latika Gupta
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Beverly Ng
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Hannah Jethwa
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Nick De Windt
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Tania Gudu
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Joseph Hutton
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Denis O'Sullivan
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Michele M. Luchetti
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Matthew Stoll
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Jasvinder A. Singh
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Rosario Peluso
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Judith Rademacher
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
M. Elaine Husni
DRJ acknowledges research support from the Cambridge Arthritis Research Endeavour and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). D.R. Jadon, MBBCh, PhD, Department of Rheumatology, University of Cambridge, Cambridge, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, California, USA; T. Raine, MB, BChir, PhD, Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; F. Rieder, MD, Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA; S. Siebert, MD, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK; M. Zummer, MD, Division of Rheumatology, CH Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada; S. Schwartzman, MD, Hospital for Special Surgery, Weill Cornell Medical Center, New York City, New York, USA; J.T. Rosenbaum, MD, Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, and the Legacy Devers Eye Institute, Portland, Oregon, USA; B. Michelsen, MD, PhD, Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway; R. Laxminarayan, MD, University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on-Trent, UK; D. Wu, PhD, Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; L. Gupta, MD, DM, Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, and Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, UK; B. Ng, MBBS, MSc, Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; H. Jethwa, MBChB, PhD, Department of Rheumatology, Royal Free London NHS Foundation Trust, Imperial College Healthcare NHS Trust, London, UK; N. De Windt, BS, Department of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA; T. Gudu, MD, PhD, Rheumatology Department, Cambridge University Hospitals NHS FT, Cambridge, UK; J. Hutton, MBChB, University of Cambridge, Cambridge, UK; D. O'Sullivan, BE, Rheumatic & Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Dublin, Ireland; M.M. Luchetti, MD, Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; M. Stoll, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA; J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama at Birmingham, and Department of Epidemiology at the UAB School of Public Health, Birmingham, Alabama, USA; R. Peluso, MD, PhD, Department of Clinical Medicine and Surgery, Rheumatology Research Unit, School of Medicine, University Federico II of Naples, Naples, Italy; J. Rademacher, MD, Department of Gastroenterology, Infection, and Rheumatology, Universitätsmedizin Berlin, and Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. DRJ has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including from AbbVie, Amgen, Biogen, Celgene, Lilly, Ferris, Fresenius Kabi, Galapagos/Gilead, GSK, Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. ERS has participated in advisory boards, given conferences, or received grants from AbbVie, Amgen, BMS, Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has been a consultant to AbbVie, Amgen, Lilly, Janssen, Novartis, and UCB. TR has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, BI, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, and UCB. FR has provided consulting or been on the advisory board for Adnovate, Agomab, Allergan, AbbVie, Arena, BI, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis, Index, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. S. Siebert has received institutional research funding from Amgen (previously Celgene), BI, BMS, Lilly, Janssen, and UCB; and honoraria/speaker fees from AbbVie, Biogen, Celgene, GSK, Janssen, Novartis, and UCB. MZ has been on the research/ speaker/advisory boards for AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Sandoz, and Pfizer. S. Schwartzman has been a speaker for AbbVie, Jannssen, Lilly, Pfizer, Novartis, and UCB; a consultant for AbbVie, Janssen, Lilly, Myriad, Novarits, Regeneron, Sanofi, UCB, Stelexis, Jubilant, and Teijin; and is a board member of the National Psoriasis Foundation and is on the scientific advisory board of Myriad. JTR has provided consulting for Gilead, AbbVie, Novartis, Revolo, Affibody, Neoluekin, Corvus, Horizon, Roivant, and Priovant; received research support from Horizon, Pfizer, and the Malassezia Foundation; received royalties from UpToDate; and been on the data monitoring committee for Celgene/BMS and Clinical Endpoints Committee for Lilly. BM received a research grant from Novartis. RL received a research grant, an education grant, and has been a speaker for Lilly, AbbVie, and Novartis. MML has received research grants, education grants, and/or speaker/advisory board honoraria from pharmaceutical companies, including AbbVie, Amgen, Lilly, Galapagos/Gilead, Janssen, Novartis, and Pfizer. MS has been a consultant for Novartis. JAS has received consultant fees from Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology; received institutional research support from Zimmer Biomet; food and beverage payments from Intuitive Surgical/ Philips Electronics North America; owns stock options in TPT Global Tech, Vaxart, Atyu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris, Enzolytics, Seres, Tonix, Charlotte's Web; and is on the speaker's bureau of Simply Speaking. JR received support for attending meetings or travel from AbbVie, Novartis, and UCB. MEH received speaker and advisory fees from AbbVie, BMS, Pfizer, Novartis, Lilly, Janssen, and UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D.R. Jadon, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Email: dj351@medschl.cam.ac.uk. Accepted for publication June 28, 2022.
Abstract
Objective Several advanced therapies have been licensed across the related conditions of psoriatic arthritis (PsA), Crohn disease (CD), ulcerative colitis (UC), and noninfectious uveitis. We sought to summarize results from randomized controlled trials (RCTs) investigating the efficacy and safety of advanced therapies for these related conditions in patients with PsA.
Methods We updated the previous systematic search conducted in 2013 with literature reviews of MEDLINE, Embase, and the Cochrane Library (from February 2013 to August 2020) on this subject; only those new studies are presented here. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.
Results The number of RCTs meeting eligibility criteria were 12 for CD, 15 for UC, and 5 for uveitis. The tumor necrosis factor inhibitor (TNFi) class appears to be efficacious and safe across CD, UC, and uveitis, with the exception of etanercept. Interleukin 12/23 inhibitors (IL-12/23i) are efficacious for CD and UC. Phase II and III RCTs of Janus kinase inhibitors (JAKi) and IL-23i in CD and UC are promising in terms of efficacy and safety. IL-17i must be used with great caution in patients with PsA at high risk of inflammatory bowel disease (IBD). RCTs in uveitis have mainly studied adalimumab.
Conclusion We have identified 32 recent RCTs in IBD and uveitis and updated recommendations for managing patients with PsA and these related conditions. A multispecialty approach is essential to effectively, safely, and holistically manage such patients. Advanced therapies are not equally efficacious across these related conditions, with dosing regimens and safety varying.
In this issue
The Journal of Rheumatology
Vol. 50, Issue 1
1 Jan 2023
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations
Deepak R. Jadon, Nadia Corp, Danielle A. van der Windt, Laura C. Coates, Enrique R. Soriano, Arthur Kavanaugh, Tim Raine, Florian Rieder, Stefan Siebert, Michel Zummer, Sergio Schwartzman, James T. Rosenbaum, Brigitte Michelsen, Ramasharan Laxminarayan, Dongze Wu, Latika Gupta, Beverly Ng, Hannah Jethwa, Nick De Windt, Tania Gudu, Joseph Hutton, Denis O'Sullivan, Michele M. Luchetti, Matthew Stoll, Jasvinder A. Singh, Rosario Peluso, Judith Rademacher, M. Elaine Husni
The Journal of Rheumatology Dec 2022, jrheum.220317; DOI: 10.3899/jrheum.220317
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations
Deepak R. Jadon, Nadia Corp, Danielle A. van der Windt, Laura C. Coates, Enrique R. Soriano, Arthur Kavanaugh, Tim Raine, Florian Rieder, Stefan Siebert, Michel Zummer, Sergio Schwartzman, James T. Rosenbaum, Brigitte Michelsen, Ramasharan Laxminarayan, Dongze Wu, Latika Gupta, Beverly Ng, Hannah Jethwa, Nick De Windt, Tania Gudu, Joseph Hutton, Denis O'Sullivan, Michele M. Luchetti, Matthew Stoll, Jasvinder A. Singh, Rosario Peluso, Judith Rademacher, M. Elaine Husni
The Journal of Rheumatology Dec 2022, jrheum.220317; DOI: 10.3899/jrheum.220317
